Table 5.
Indinavir population pharmacokinetic parameters of the final model
| Estimation | ||||
|---|---|---|---|---|
| Parameter | Final estimate | SE of the estimate | 95% CI | 95% CI on the difference |
| CL/F (l h−1) | ||||
| With RTV | 26.3 | 2.85 | 20.6, 32.0 | 5.8, 26.2 |
| Without RTV | 42.3 | 4.33 | 33.6, 51.0 | |
| V/F (l) | 69.9 | 5.84 | 58.2, 81.6 | |
| ka (h−1) | ||||
| MDR1 3435CC | 2.96 | 0.94 | 1.08, 4.84 | 0.37, 5.53* |
| MDR1 3435CT | 5.91 | 0.92 | 4.07, 7.75 | |
| MDR1 3435TT | 3.22 | 1.12 | 0.98, 5.46 | |
| Intersubject variability (ω2) (% coefficient of variation) | ||||
| ω2 (CL/F) | 0.19 (43%) | 0.06 | 0.07, 0.31 | |
| ω2 (V/F) | 0.31 (55%) | 0.11 | 0.09, 0.53 | |
| ω2 (ka) | 6.7 (258%) | 5.83 | 4.96, 18.36 | |
| Residual variability (σ2) | ||||
| σ2 proportional | 0.18 (42%) | 0.02 | 0.14, 0.22 | |
| σ2 additive (ng ml−1) | 198 | 35.1 | 127.8, 268.2 | |
CL/F clearance; V/F volume of distribution; karate of absorption constant; 95% CI 95% confidence interval
*
95% CI on the difference between CC genotype and CT genotype